1. Home
  2. BATRA vs VRDN Comparison

BATRA vs VRDN Comparison

Compare BATRA & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlanta Braves Holdings Inc. Series A

BATRA

Atlanta Braves Holdings Inc. Series A

HOLD

Current Price

$42.35

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$30.46

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BATRA
VRDN
Founded
1991
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BATRA
VRDN
Price
$42.35
$30.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$58.00
$40.45
AVG Volume (30 Days)
52.1K
1.4M
Earning Date
02-25-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$723,307,000.00
$70,789,000.00
Revenue This Year
$12.40
$26,257.62
Revenue Next Year
$6.78
$10.69
P/E Ratio
N/A
N/A
Revenue Growth
6.62
23340.07
52 Week Low
$38.67
$9.90
52 Week High
$50.50
$34.04

Technical Indicators

Market Signals
Indicator
BATRA
VRDN
Relative Strength Index (RSI) 46.02 46.71
Support Level $42.30 $28.96
Resistance Level $44.05 $31.54
Average True Range (ATR) 0.71 1.07
MACD -0.03 -0.45
Stochastic Oscillator 17.03 34.10

Price Performance

Historical Comparison
BATRA
VRDN

About BATRA Atlanta Braves Holdings Inc. Series A

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: